55 Recruiting Myelofibrosis Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Browse by Study Phase
Top Interventions for Myelofibrosis
Related Conditions
Top Recruiting Myelofibrosis Studies
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
📍 University of Alabama At Birmingham — Birmingham, Alabama
View Study & Checklist ➔Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis
📍 Tom Baker Cancer Centre — Calgary, Alberta
View Study & Checklist ➔Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
📍 UAB Division of Hematology/Oncology — Birmingham, Alabama
View Study & Checklist ➔Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
📍 The Oncology Institute of Hope and Innovation — Pasadena, California
View Study & Checklist ➔A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
📍 Local Institution - 0069 — Newport Beach, California
View Study & Checklist ➔A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
📍 University of California-San Diego/Moores UCSD Cancer Center — La Jolla, California
View Study & Checklist ➔A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
📍 City of Hope — Duarte, California
View Study & Checklist ➔A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis
📍 MD Andersson Cancer Hospital — Houston, Texas
View Study & Checklist ➔Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)
📍 Thomas Jefferson University — Philadelphia, Pennsylvania
View Study & Checklist ➔A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis
📍 Memorial Sloan Kettering Monmouth — Middletown, New Jersey
View Study & Checklist ➔Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)
📍 Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
View Study & Checklist ➔Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
📍 The University of Kansas Cancer Center-Westwood — Westwood, Kansas
View Study & Checklist ➔Revumenib in Patients With Myelofibrosis
📍 Icahn School of Medicine at the Mount Sinai Hospital — New York, New York
View Study & Checklist ➔Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
📍 UC Davis Health — Sacramento, California
View Study & Checklist ➔AlloHCT With PegINFa for Myelofibrosis
📍 Huntsman Cancer Institute at the University of Utah — Salt Lake City, Utah
View Study & Checklist ➔Therapeutic RSK1 Targeting in Myelofibrosis
📍 Washington University School of Medicine — St Louis, Missouri
View Study & Checklist ➔A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
📍 University of Alabama — Birmingham, Alabama
View Study & Checklist ➔A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
📍 Massachusetts General Hospital (Data Collection Only) — Boston, Massachusetts
View Study & Checklist ➔Momelotinib During and After HCT in Myelofibrosis
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
📍 UAB Hospital — Birmingham, Alabama
View Study & Checklist ➔Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
📍 Center for International Blood and Marrow Transplant Research — Minneapolis, Minnesota
View Study & Checklist ➔Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
📍 Chao Family Comprehensive Cancer Center, University of California, Irvine — Orange, California
View Study & Checklist ➔A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
View Study & Checklist ➔A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
📍 City of Hope - Duarte Main Site — Duarte, California
View Study & Checklist ➔Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
📍 Icahn School of Medicine at Mount Sinai — New York, New York
View Study & Checklist ➔Quantitative MRI for Myelofibrosis
📍 University of Michigan Hospital — Ann Arbor, Michigan
View Study & Checklist ➔Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔